Novo Nordisk Liraglutide Filing Planned In Q2 2008 For Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Final Phase III study in LEAD program shows benefit after one year of monotherapy with the once-daily human GLP-1 analogue.
You may also be interested in...
Liraglutide Up For Approval In U.S. And Europe
Novo Nordisk’s type 2 diabetes drug could face hurdles once longer-acting GLP-1s hit the market.
Liraglutide Up For Approval In U.S. And Europe
Novo Nordisk’s type 2 diabetes drug could face hurdles once longer-acting GLP-1s hit the market.
Novo Nordisk Plans GLP-1 Analogue Expansion To Treat Diabetes, Obesity
Firm on track for liraglutide U.S., EU filings in second quarter; Japan filing in third quarter.